JP2021521266A5 - - Google Patents
Info
- Publication number
- JP2021521266A5 JP2021521266A5 JP2020569776A JP2020569776A JP2021521266A5 JP 2021521266 A5 JP2021521266 A5 JP 2021521266A5 JP 2020569776 A JP2020569776 A JP 2020569776A JP 2020569776 A JP2020569776 A JP 2020569776A JP 2021521266 A5 JP2021521266 A5 JP 2021521266A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently selected
- compound according
- groups
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862670323P | 2018-05-11 | 2018-05-11 | |
| US62/670,323 | 2018-05-11 | ||
| PCT/US2019/032043 WO2019217972A1 (en) | 2018-05-11 | 2019-05-13 | Kdm1a inhibitors for the treatment of disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521266A JP2021521266A (ja) | 2021-08-26 |
| JP2021521266A5 true JP2021521266A5 (enExample) | 2022-05-16 |
| JP7450559B2 JP7450559B2 (ja) | 2024-03-15 |
Family
ID=68468431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020569776A Active JP7450559B2 (ja) | 2018-05-11 | 2019-05-13 | 疾患の処置のためのｋｄｍ１ａ阻害剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11578059B2 (enExample) |
| EP (1) | EP3790867B1 (enExample) |
| JP (1) | JP7450559B2 (enExample) |
| KR (1) | KR102684364B1 (enExample) |
| CN (1) | CN112513020B (enExample) |
| AU (1) | AU2019265022B2 (enExample) |
| BR (1) | BR112021001066A2 (enExample) |
| CA (1) | CA3103392A1 (enExample) |
| ES (1) | ES2977656T3 (enExample) |
| IL (1) | IL279260B2 (enExample) |
| PH (1) | PH12020552135A1 (enExample) |
| SG (1) | SG11202012289UA (enExample) |
| WO (1) | WO2019217972A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2734209T3 (es) | 2013-08-06 | 2019-12-04 | Imago Biosciences Inc | Inhibidores de KDM1A para el tratamiento de enfermedades |
| CA2976350C (en) | 2015-02-12 | 2023-09-19 | Hugh Young Rienhoff, Jr. | Kdm1a inhibitors for the treatment of disease |
| CN111194306B (zh) | 2016-08-16 | 2023-05-16 | 伊美格生物科学公司 | 用于制备kdm1a抑制剂的方法和过程 |
| EP3790867B1 (en) | 2018-05-11 | 2024-03-27 | Imago Biosciences Inc. | Kdm1a inhibitors for the treatment of disease |
| KR20220113753A (ko) * | 2019-12-09 | 2022-08-16 | 이마고 바이오사이언시즈 인코포레이티드 | 골수증식성 신생물의 치료를 위한 리신-특이적 히스톤 데메틸라제 억제제 |
| US20240216357A1 (en) * | 2021-03-24 | 2024-07-04 | Sichuan Huiyu Pharmaceutical Co., Ltd. | Polycyclic compound and application thereof |
| CN114591324B (zh) * | 2021-03-30 | 2023-05-05 | 深圳微芯生物科技股份有限公司 | 一类吡嗪酮衍生物、其制备及其应用 |
| US20250073232A1 (en) | 2021-04-08 | 2025-03-06 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors for treating myeloid cancers |
| US20250295660A1 (en) | 2022-05-09 | 2025-09-25 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
| EP4522136A1 (en) | 2022-05-09 | 2025-03-19 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
| US20260085082A1 (en) * | 2022-12-23 | 2026-03-26 | Imago Biosciences, Inc. | Kdm1a inhibitors for the treatment of disease |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006037028A2 (en) * | 2004-09-24 | 2006-04-06 | Idenix (Cayman) Limited | Methods and compositions for treating flaviviruses, pestiviruses and hepacivirus |
| MX2009008531A (es) * | 2007-02-16 | 2009-08-26 | Amgen Inc | Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met. |
| JP5140154B2 (ja) * | 2007-06-27 | 2013-02-06 | アストラゼネカ・アクチエボラーグ | ピラジノン誘導体および肺疾患の処置におけるそれらの使用 |
| EP2198018B1 (en) | 2007-09-13 | 2013-11-20 | Codexis, Inc. | Ketoreductase polypeptides for the reduction of acetophenones |
| HUE027683T2 (en) | 2007-10-01 | 2016-10-28 | Codexis Inc | Ketoreductase polypeptides for the production of azetidinone |
| WO2010025287A2 (en) | 2008-08-27 | 2010-03-04 | Codexis, Inc. | Ketoreductase polypeptides for the production of 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine |
| EP2177502A1 (en) | 2008-10-17 | 2010-04-21 | Oryzon Genomics, S.A. | Compounds and their use |
| WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| JPWO2010143582A1 (ja) | 2009-06-11 | 2012-11-22 | 公立大学法人名古屋市立大学 | フェニルシクロプロピルアミン誘導体及びｌｓｄ１阻害剤 |
| US8415381B2 (en) | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
| US8859555B2 (en) | 2009-09-25 | 2014-10-14 | Oryzon Genomics S.A. | Lysine Specific Demethylase-1 inhibitors and their use |
| EP2486002B1 (en) | 2009-10-09 | 2019-03-27 | Oryzon Genomics, S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
| CA2796726C (en) | 2010-04-19 | 2021-02-16 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
| BR112012027062B8 (pt) | 2010-04-20 | 2021-05-25 | Fond Ieo | composto, processo para a preparação de um composto e usos do mesmo |
| US9006449B2 (en) | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
| BR112013002164B1 (pt) | 2010-07-29 | 2021-11-09 | Oryzon Genomics S.A. | Inibidores de desmetilase à base de arilciclopropilamina de lsd1, seus usos, e composição farmacêutica |
| WO2012034116A2 (en) | 2010-09-10 | 2012-03-15 | The Johns Hopkins University | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| WO2012047852A2 (en) | 2010-10-07 | 2012-04-12 | The J. David Gladstone Institutes | Compositions and methods for modulating immunodeficiency virus transcription |
| US9061966B2 (en) | 2010-10-08 | 2015-06-23 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012071469A2 (en) | 2010-11-23 | 2012-05-31 | Nevada Cancer Institute | Histone demethylase inhibitors and uses thereof for treatment o f cancer |
| EP2712315B1 (en) | 2011-02-08 | 2021-11-24 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| EP2712316A1 (en) | 2011-02-08 | 2014-04-02 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders |
| PH12013501871A1 (en) | 2011-03-25 | 2019-06-03 | Glaxosmithkline Ip No 2 Ltd | Cyclopropylamines as lsd1 inhibitors |
| PE20141202A1 (es) | 2011-08-09 | 2014-10-03 | Takeda Pharmaceutical | Compuesto de ciclopropanoamina |
| EP2768805B1 (en) | 2011-10-20 | 2020-03-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| JP6046154B2 (ja) | 2011-10-20 | 2016-12-14 | オリソン ヘノミクス エセ． アー． | Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物 |
| WO2014084298A1 (ja) | 2012-11-28 | 2014-06-05 | 京都府公立大学法人 | リシン構造を有するｌｓｄ1選択的阻害薬 |
| EP2740474A1 (en) | 2012-12-05 | 2014-06-11 | Instituto Europeo di Oncologia S.r.l. | Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
| WO2014164867A1 (en) | 2013-03-11 | 2014-10-09 | Imago Biosciences | Kdm1a inhibitors for the treatment of disease |
| CA2916533C (en) | 2013-06-25 | 2022-12-20 | University Of Canberra | Methods and compositions for modulating cancer stem cells |
| ES2734209T3 (es) | 2013-08-06 | 2019-12-04 | Imago Biosciences Inc | Inhibidores de KDM1A para el tratamiento de enfermedades |
| EP3105218B1 (en) | 2014-02-13 | 2019-09-25 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| CN121203988A (zh) | 2014-04-22 | 2025-12-26 | C-乐克塔股份有限公司 | 酮还原酶 |
| DK3160956T3 (da) * | 2014-06-27 | 2020-08-31 | Celgene Quanticel Res Inc | Inhibitorer af lysin-specifik demethylase-1 |
| CA2976350C (en) * | 2015-02-12 | 2023-09-19 | Hugh Young Rienhoff, Jr. | Kdm1a inhibitors for the treatment of disease |
| WO2017075367A1 (en) * | 2015-10-28 | 2017-05-04 | Northwestern University | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2) |
| US20190070172A1 (en) | 2015-11-05 | 2019-03-07 | Imago Biosciences, Inc. | Lysine-specific histone demethylase as a novel therapeutic target in myeloproliferative neoplasms |
| US9809541B2 (en) * | 2015-12-29 | 2017-11-07 | Mirati Therapeutics, Inc. | LSD1 inhibitors |
| PT3455204T (pt) * | 2016-05-09 | 2026-01-27 | Jubilant Epicore LLC | Compostos de ciclopropil-amida como inibidores duplos de lsd1/hdac |
| WO2018035249A1 (en) | 2016-08-16 | 2018-02-22 | Imago Biosciences, Inc. | Compositions and methods for producing stereoisomerically pure aminocyclopropanes |
| CN111194306B (zh) | 2016-08-16 | 2023-05-16 | 伊美格生物科学公司 | 用于制备kdm1a抑制剂的方法和过程 |
| MA51507A (fr) | 2016-12-09 | 2020-11-11 | Constellation Pharmaceuticals Inc | Marqueurs pour un traitement personnalisé du cancer avec des inhibiteurs de lsd1 |
| EP3790867B1 (en) | 2018-05-11 | 2024-03-27 | Imago Biosciences Inc. | Kdm1a inhibitors for the treatment of disease |
-
2019
- 2019-05-13 EP EP19800758.5A patent/EP3790867B1/en active Active
- 2019-05-13 SG SG11202012289UA patent/SG11202012289UA/en unknown
- 2019-05-13 AU AU2019265022A patent/AU2019265022B2/en active Active
- 2019-05-13 US US17/054,126 patent/US11578059B2/en active Active
- 2019-05-13 ES ES19800758T patent/ES2977656T3/es active Active
- 2019-05-13 IL IL279260A patent/IL279260B2/en unknown
- 2019-05-13 JP JP2020569776A patent/JP7450559B2/ja active Active
- 2019-05-13 CN CN201980046308.0A patent/CN112513020B/zh active Active
- 2019-05-13 BR BR112021001066-1A patent/BR112021001066A2/pt unknown
- 2019-05-13 WO PCT/US2019/032043 patent/WO2019217972A1/en not_active Ceased
- 2019-05-13 CA CA3103392A patent/CA3103392A1/en active Pending
- 2019-05-13 KR KR1020207035544A patent/KR102684364B1/ko active Active
-
2020
- 2020-12-11 PH PH12020552135A patent/PH12020552135A1/en unknown
-
2022
- 2022-12-15 US US18/066,667 patent/US11932629B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021521266A5 (enExample) | ||
| CN111971279B (zh) | 趋化因子受体调节剂及其用途 | |
| RU2768827C2 (ru) | Модуляторы хемокинового рецептора и их применение | |
| ES2841912T3 (es) | Inhibidores de CXCR2 | |
| ES2657839T3 (es) | Compuestos de pirazolopirimidina inhibidores de JAK y métodos | |
| ES2712973T3 (es) | Inhibidores de MDM2 y métodos terapéuticos que usan los mismos | |
| CN112154142B (zh) | 整合应激通路的调节剂 | |
| KR20250029954A (ko) | 피리도[4,3-d]피리미딘 화합물 | |
| JP5760010B2 (ja) | １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用 | |
| JP2021107415A (ja) | 統合ストレス経路のモジュレーター | |
| JP6382831B2 (ja) | アポトーシス阻害タンパク質（ｉａｐ）のアンタゴニスト | |
| JP2025114615A (ja) | 治療薬としての細胞毒素のペプチドコンジュゲート | |
| RU2016118768A (ru) | Композиции, пригодные для лечения расстройств, связанных с kit | |
| EP3996711B1 (en) | Indanes as pd-l1 inhibitors | |
| JP2021501788A (ja) | 統合的ストレス経路の調節剤 | |
| ES2715104T3 (es) | Nuevos derivados de pirazolopirimidina como inhibidores de nik | |
| JP2021501780A (ja) | 統合的ストレス経路の調節剤 | |
| CN106488910A (zh) | Kras g12c的抑制剂 | |
| JP2016525529A5 (enExample) | ||
| EA032639B1 (ru) | Гидрохлоридные соли n-(цианометил)-4-(2-(4-морфолинофениламино)пиримидин-4-ил)бензамида | |
| RU2016106003A (ru) | Новые изоиндолиновые или изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
| US12006320B2 (en) | Heterocyclic derivatives as PI3K inhibitors | |
| KR20250100539A (ko) | 피리도[4,3-d]피리미딘 화합물 | |
| BR112020001949A2 (pt) | composto, composição farmacêutica, e, métodos para tratar um linfoma não hodgkin e para tratar um linfoma ou uma leucemia | |
| ES3032458T3 (en) | Crystalline form of the hydrochloride salt of 2-((1r,4r)-4-((3-(3-(trifluoromethyl)phenyl) imidazo[1,2-b]pyridazin-6-yl)amino)cyclohexyl)propan-2-ol |